FDA Approves Glaukos Labeling Supplement Allowing iDose TR Re-Administration
I'm PortAI, I can summarize articles.
Glaukos Corporation has received FDA approval for a labeling supplement to its iDose® TR product, allowing for re-administration under a repeat treatment protocol. This decision is supported by clinical evidence demonstrating the safety and tolerability of repeated use, provided patients maintain a healthy cornea. Physicians can now administer iDose TR multiple times, as confirmed by clinical studies. This news is for informational purposes only and should not be considered financial or legal advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments